Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Zydus Lifesciences and Guardant Health, Inc., a leading precision oncology company, have an exclusive agreement to make the Shield™ Multi-Cancer Detection (MCD) test available in India, for which Zydus has signed a Memorandum of Understanding (MoU) with Apollo Hospitals to offer the test in the territory.
The Shield MCD test is a methylation-based blood test for the detection of multiple cancer types including bladder, colorectal, breast, prostate, oesophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 45 or older and who are at typical average risk for cancer. With just a blood draw, the test screens for 10 of the most common cancers, many of which have high mortality rates in India. The test has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA), recognising its potential to provide more effective screening for cancers than existing options.
Under an exclusive agreement with Zydus Lifesciences, Guardant Health will commercialise the Shield MCD test in India, while Apollo Hospitals will offer the test through its healthcare network.
The Shield MCD test is a methylation-based blood test for the detection of multiple cancer types including bladder, colorectal, breast, prostate, oesophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 45 or older and who are at typical average risk for cancer. The test has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA), recognising its potential to provide more effective screening for cancers than existing options.
Speaking on this development, Dr. Prathap C. Reddy, chairman, Apollo Hospitals Group, said, 'At Apollo, we have long believed that the most effective healthcare is proactive healthcare. The future of medicine lies not only in treating disease, but in preventing it and detecting it at its earliest, most treatable stages. Cancer continues to be one of the greatest health challenges facing societies worldwide, and expanding access to timely, reliable screening, is critical to reducing its impact. Our collaboration with Zydus Lifesciences marks an important milestone in advancing accessible, patient-friendly cancer screening solutions for the people of India.”
Dr. Sharvil Patel, managing director, Zydus Lifesciences, said, “As India’s leading oncology company, we are reimagining the role of diagnostics in cancer care. We are pleased to partner with Apollo Hospitals and Guardant Health to introduce Shield MCD in India, expanding access to an innovative screening technology that complements existing screening pathways.”
Simranjit Singh, chief executive officer, Guardant Health AMEA added, 'We are pleased to bring the Shield Multi-Cancer Detection (MCD) test to India through Apollo Cancer Centres and our longstanding commercial partner Zydus Lifesciences. Earlier detection has the potential to transform cancer outcomes, and Shield MCD represents an important advancement in helping identify cancer-associated signals through a single blood draw.”
Zydus Lifesciences is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
Apollo Hospitals was established in 1983 by Dr. Prathap C Reddy, renowned architect of modern healthcare in India. It has a robust presence across the healthcare ecosystem, including Hospitals, Pharmacies, Primary Care & Diagnostic Clinics and several Retail Health models.
For the full year,net profit rose 34.29% to Rs 1941.70 crore in the year ended March 2026 as against Rs 1445.90 crore during the previous year ended March 2025. Sales rose 15.76% to Rs 25228.50 crore in the year ended March 2026 as against Rs 21794.00 crore during the previous year ended March 2025.
JBM Auto Ltd, Apollo Hospitals Enterprise Ltd, Tube Investments of India Ltd, Tata Consumer Products Ltd are among the other stocks to see a surge in volumes on BSE today, 11 May 2026.
V-Guard Industries Ltd notched up volume of 5.14 lakh shares by 10:47 IST on BSE, a 24.37 fold spurt over two-week average daily volume of 21094 shares. The stock slipped 0.47% to Rs.329.80. Volumes stood at 12592 shares in the last session.
JBM Auto Ltd witnessed volume of 6.6 lakh shares by 10:47 IST on BSE, a 9.77 times surge over two-week average daily volume of 67522 shares. The stock increased 4.32% to Rs.678.00. Volumes stood at 1.44 lakh shares in the last session.
Apollo Hospitals Enterprise Ltd registered volume of 90671 shares by 10:47 IST on BSE, a 8.47 fold spurt over two-week average daily volume of 10705 shares. The stock slipped 0.12% to Rs.8,085.00. Volumes stood at 37471 shares in the last session.
Tube Investments of India Ltd recorded volume of 2.53 lakh shares by 10:47 IST on BSE, a 7.29 times surge over two-week average daily volume of 34620 shares. The stock lost 2.29% to Rs.2,978.40. Volumes stood at 1.69 lakh shares in the last session.
Tata Consumer Products Ltd registered volume of 5.25 lakh shares by 10:47 IST on BSE, a 6.14 fold spurt over two-week average daily volume of 85592 shares. The stock rose 3.38% to Rs.1,215.65. Volumes stood at 1 lakh shares in the last session.